Abstract：Objective To explore the effect of entecavir on immunologic functions of patients with chronic hepatitis B.Methods Totally 231 patients with chronic hepatitis B were selected and randomly divided into observation group (116 cases) and control group (115 cases). Routine liver-protecting treatment was given to control group, and observation group was added with entecavir. The level of HBV-DNA, liver function indexes and change of immunologic functions were observed.Results After treatment, the level of HBV-DNA was lower and the improvement of liver function indexes were better in observation group than those in control group, and there was statistically significant difference (P＜0.05). The level of CD4+T cells and their ratio to CD8+T cells were significantly increased, the percentage of CD5+CD19+ B cells was obviously decreased, and the level of C3, C4 was significantly increased in observation group after treatment. Conclusion with control group, the difference was of statistical significance (P＜0.05). There were no serious adverse reactions in either group.Conclusion Entecavir, which is safe for chronic hepatitis B, can reduce the expression of HBV DNA , improve the liver functions and immunological functions.
袁宇慧, 程辉. 恩替卡韦对慢性乙型肝炎患者免疫功能的影响[J]. 解放军预防医学杂志, 2016, 34(5): 712-714.
YUAN Yuhui, CHENG Hui. Influence of Entecavir on Immunologic Functions of Patients with Chronic Hepatitis B. Journal of Preventive Medicine of Chinese People's Liberation Army, 2016, 34(5): 712-714.
[1] LIU J,KOSINSKA A,LU M,et al.New therapeutic vaccination strategies for the treatment of chronic hepatitis B[J].Plos Genetics,2014,29(1):10. [2] 李正康,李杰,庄辉.乙型肝炎疫苗免疫应答宿主相关遗传因素研究进展[J].中国病毒病杂志,2014,(4):316. [3] 冯歆夏,田德安.乙型肝炎炎症微环境与肝癌发生及预后关系的研究进展[J].临床内科杂志,2014,31(2):80. [4] 巫翠萍,覃西,王华民,等.慢性乙型肝炎患者外周血CD4+CD25+Treg与CD4+和CD8+T淋巴细胞亚群的相关研究[J].中国免疫学杂志,2010,26(3):273. [5] WONG G L,CHAN H L,MAK C W,et al.Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis[J].Hepatology,2013,58(5):1537. [6] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华流行病学杂志,2011,16(9):405. [7] MONTA O L,ARANGUIBEL F,BOFFILL M,et al.An analysis of the composition of the inflammatory infiltrate in autoimmune and hepatitis B virus-induced chronic liver disease[J].Hepatology,1983,3(3):292. [8] LI M,SUN X H,ZHU X J,et al.HBcAg induces PD-1 upregulation on CD4+T cells through activation of JNK,ERK and PI3K/AKT pathways in chronic hepatitis-B-infected patients[J].Lab Invest,2012,92(2):295 [9] TIAN Z F,YOU Z L,YI H,et al.Effect of entecavir on CD4+T-cell subpopulations in patients with chronic hepatitis B[J].Ann Hepatol, 2016,15(2):174. [10] 刘良忠.滤泡辅助性T淋巴细胞与B淋巴相互作用在慢性乙型肝炎的研究[D].重庆医科大学,2011. [11] 龚燕萍,张红星,赵超,等.IL-10+CD19+调节性B淋巴细胞在慢性乙型肝炎患者外周血中的表达[J].中华检验医学杂志,2014,37(2):100. [12] 杨金华,介绍亮,吴萌,等.CD19+CD5+B细胞和白细胞介素-10在系统性红斑狼疮患者外周血中的变化及意义[J].中华风湿病学杂志,2015,19(7):447. [13] 饶莉,何世东,于乐,等.类风湿关节炎患者外周血CD5+B细胞及其亚群变化和意义[J].中国综合临床,2009,25(5):502. [14] 王一浩,付蓉,刘惠,等.免疫相关性全血细胞减少患者记忆B淋巴细胞(CD5+CD19+CD27+)亚群的临床意义研究[J].中华血液学杂志,2014,35(8):719. [15] MARKELJEVI J,BATINI D,UZAREVI B,et al.Peripheral blood CD5+ B cell subset in the remission phase of systemic connective tissue diseases[J].J Rheumatol,1994,21(12):2225. [16] MORBACH H,SINGH S K,FABER C,et al.Analysis of RAG expression by peripheral blood CD5+ and CD5- B cells of patients with childhood systemic lupus erythematosus[J].Ann Rheum Dis,2006,65(4):482. [17] 张红,李光迪,杨佩琦,等.血清补体C3在慢性乙型肝炎检测中的应用价值[J].检验医学与临床,2010,7(10):953. [18] 方海俊,何雄平,骆婷婷.补体C3、C4水平对病毒性肝炎患者的临床意义[J].中国卫生检验杂志,2015,(8):1283. [19] 林孟新,苏智军,郭如意,等.恩替卡韦治疗慢性乙型肝炎患者外周血T细胞亚群和补体的变化[J].实用肝脏病杂志,2013,(4):354. [20] 赵朋涛,李泽鹏,池晓玲,等.血清补体C3和C4对慢性乙型肝炎患者肝组织病理状态的预测价值[J].肝脏,2012,17(10):712.
2016, Vol. 34 
